Company Description: Suntec has a proprietary MINC (Multi-target Immune-modulation Nanocomplex) technology platform to develop highly effective and safe immunotherapies. MINC applies to neurodegenerative diseases such as Alzheimer's, Parkinson's and immunotherapies for cancer, vaccine, and autoimmune diseases. Suntec has a pipeline of 6 drug candidates in pre-clinical development stage with potentials of "breakthrough"designations. STM-001 was awarded with NIH support to treat breast, ovarian, gastric, glioma and brain-metastatic cancers. STM-002 in combination with anti-PD-1/PD-L1 can bring the total efficacy/response to 60% (vs 20% for anti-PD-1/PD-L1 alone). Both candidates will enter human trials in 2024. Suntec has 3 drug candidates for Alzheimer’s (AD) and Parkinson’s (PD) diseases. MINC vehicles carry protein drugs to the brain in high concentrations. Without the MINC platform, these proteins penetrate the brain at 0.001-0.1%. With the MINC platform, they penetrate a wobbly 4-10%. MINC also reduces brain edema caused by these protein drugs and reduces neural cell death and promotes neural cell regeneration to recover cognitive behavior for AD/PD patients.